Abstract Library

#878 Evidence of Improved Survival When Patients are Referred on to a Specialist NET Clinic with Multidisciplinary Team Management

Introduction: ENETs and UKINETs Guidelines emphasize that patients with NETs should be referred to NET specialist clinics (NSC) and these clinics should use a multidisciplinary team (MDT) for decision making. In Belfast there has been an NSC for several decades and an MDT since 2000.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Ardill J

Authors: Ardill J, McCance D, Johnston B,

Keywords: NET Clinics,

#876 Incidence and Prevalence of Neuroendocrine Tumors (NETs) of the Ileum and Colon (Excluding Appendiceal NETs) in Northern Ireland (NI) Over a 25-Year-Period (1988-2012)

Introduction: Incidence of NETs is quoted to be 2/100,000 with approximately 25% being tumors of the midgut, (0.5/100,000). Incidence is increasing. However, this may be in part due to improved diagnosis but it is also thought to be a true increase.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Ardill J

Authors: Ardill J, Johnston B, Stronge W, Turner G, McCance D,

Keywords: MGC,

#669 Incidence of Second Malignancy in Patients with Neuroendocrine Tumors (NETs) of the Ileum and Colon (MGC)

Introduction: Increased incidence of second malignancy is observed in NETs (Kamp et al 2012).

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Ardill J

Authors: Ardill J, Johnston B, Stronge W, Turner G, McCance D,

Keywords: second malignancy, MGC,colon cancer,

#580 Diagnostic Performance of Dual Tracer PET/CT in Staging Neuroendocrine Tumors of the Lung

Introduction: Different positron emission tomography/computed tomography (PET/CT) tracers may be useful in staging lung neuroendocrine tumors (LNETs)

Conference:

Presenting Author:

Authors: Treglia G, Stefanelli A, Cardillo G, Lococo F, Rindi G,

Keywords: Neuroendocrine tumors, lung carcinoids, PET/CT,

#105 A pilot study using biochemical markers to predict acrcinoid heart disease in patients with carcinoid disease

Introduction: Carcinoid heart disease (CHD) affects up to 15-70% of patients with carcinoid disease. Recent ENETS guidelines recommend regular echocardiographic assessment to screen for CHD. Chromogranin A (CgA) is a peptide widely used to monitor carcinoid disease progression. Neurokinin A is a tachykinin which may be a more sensitive measure of carcinoid disease progression and prognosis. N-terminal pro Brain Naturetic Peptide is used as a screening tool for heart failure and recent results suggest utility in the diagnosis of CHD.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Wong C, Burgess M, Banks M, Ardill J, Poston G,

Keywords: carcinoid disease, chromogranin A, Neurokinin A, N-Terminal Barin Naturetic Peptide, carcinoid heart disease, echocardiography,